Solu
21 employees on LinkedIn Β· 3 known investors
Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Founders & leadership
Investors Β· 3
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AApr 2025Source β
Source: company announcements and press reports β follow each round's link for the claim.
In the news
Frequently asked questions
- What does Solu do?
- Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
- Who are Solu's investors?
- Solu's investors include Astellas Venture Management LLC, Longwood Fund, Pappas Capital.